Development of novel antibacterial peptides that kill resistant isolates

Area of Science:

• Microbiology
• Medicinal Chemistry
• Drug Discovery

Background:

• Antibiotic resistance is a growing global health threat, necessitating the development of new antimicrobial agents.
• Proline-rich cationic antibacterial peptides, like pyrrhocoricin, target bacterial protein folding via DnaK inhibition.

Purpose of the Study:

• To design and synthesize dimeric analogs of pyrrhocoricin with enhanced antibacterial properties.
• To optimize in vitro assays for evaluating peptide antibiotic efficacy.
• To assess the in vivo efficacy and stability of designed peptide analogs.

Main Methods:

• Design and solid-phase synthesis of multiply protected dimeric analogs of pyrrhocoricin.
• In vitro antibacterial assays against multidrug-resistant bacterial strains (e.g., Escherichia coli, Salmonella typhimurium).
• Assessment of peptide stability in mammalian sera and in vivo efficacy in a murine lung infection model.

Main Results:

• Pyrrhocoricin and its dimeric analogs exhibited potent activity against resistant Gram-negative bacteria at submicromolar to low micromolar concentrations.
• Designed dimers demonstrated enhanced stability in mammalian sera compared to the native peptide.
• Intranasal administration of a dimeric analog reduced bacterial load in a murine model of Haemophilus influenzae lung infection.
• Optimized synthesis facilitated large-scale laboratory preparation.

Conclusions:

• Dimeric analogs of pyrrhocoricin represent a promising class of novel antimicrobial compounds with broad-spectrum activity against resistant bacteria.
• These analogs possess improved pharmacokinetic properties, including enhanced serum stability.
• The findings support the potential of dimeric pyrrhocoricin analogs for therapeutic applications in treating bacterial infections.